Integrated Chinese Herbal Medicine and Western Medicine on the Survival in Patients with Colorectal Cancer: A Retrospective Study of Medical Records

Table 3

Survival of patients with colorectal cancer (N = 535).

Variable	Unadjusted analysis			Adjusted analysis
	HR	95% CI		Adjusted HR	95% CI
Chinese herbal medicine use
Nonusers (<30d)	1.00			1.00
Users (≥30 d)	0.62	0.44–0.88	0.007	0.54	0.38–0.77	0.001
Age (years)
≤45	1.00			—	—	—
46–65	0.52	0.31–0.88	0.014	—	—	—
>65	0.95	0.59–1.52	0.820	—	—	—
Sex
Female	1.00			—	—	—
Male	1.29	0.97–1.72	0.076	—	—	—
Clinical stage
I	1.00			1.00
II	3.25	1.58–6.70	0.001	2.98	1.44–6.18	0.003
III	3.30	1.69–6.42	<0.001	4.28	2.18–8.42	<0.001
IV	15.26	7.93–29.36	<0.001	17.49	8.90–34.38	<0.001
Surgery	0.18	0.12–0.26	<0.001	0.29	0.19–0.43	<0.001
Radiotherapy	0.82	0.60–1.12	0.215	—	—	—
Chemotherapy	0.76	0.56–1.02	0.069	0.47	0.34–0.65	<0.001
Distant metastases	5.69	4.27–7.57	<0.001	—	—	—
Comorbidity score 1	1.04	0.61–1.75	0.896	—	—	—
Comorbidity score 2	0.59	0.28–1.24	0.165	—	—	—
Comorbidity score 6	1.48	0.86–2.55	0.161	—	—	—

CI: confidence interval; HR: hazards ratio. Comorbidity score 1: myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, mild liver disease, and diabetes. Comorbidity score 2: diabetes with chronic complication, hemiplegia or paraplegia, renal disease, and malignancy (including leukemia and lymphoma). Comorbidity score 6: metastases solid tumor and acquired immune deficiency syndrome.